Annual report
7133.TEDINET S100OLLD
Period2021-04-01 → 2022-03-31
Filed2022-06-30
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.8bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥5.1bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥4.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥519m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥228m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥506m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥251m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥64m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥59m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥487m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥165m | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥328m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥97m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥33m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥14m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥13m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.5bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥1.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.5bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.5bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥609m | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥503m | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥470m | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥456m | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥720m | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥538m | at 2021-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥720m | at 2022-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥538m | at 2021-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥227m | at 2020-03-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | ¥485m | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥352m | 2020-04-01 → 2021-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥35m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥320m | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥78m | 2020-04-01 → 2021-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥165m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥17m | 2021-04-01 → 2022-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥37m | 2020-04-01 → 2021-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥6m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥95.8 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.99 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.9 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,282.04 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,199.41 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥88.28 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥306.44 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥151.36 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥42,435.9 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥41,153.85 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 42.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.3% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 39.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.5% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,499,100 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,369 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,074 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,074 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,074 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 329 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 312 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 283 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 226 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 190 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 83
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 1 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥16m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥15m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥25m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥13m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥828m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥315m |
| Care Planning Servicereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥110,000 |
| Care Planning Servicereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥84,000 |
| Care Planning Servicereportable segment | employees | at 2022-03-31 | 23 pure |
| Care Planning Servicereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥123m |
| Care Planning Servicereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥123m |
| Care Planning Servicereportable segment | segment assets | at 2022-03-31 | ¥22m |
| Care Planning Servicereportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥7m |
| Home Visit Pharmacist Servicereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥128m |
| Home Visit Pharmacist Servicereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥51m |
| Home Visit Pharmacist Servicereportable segment | employees | at 2022-03-31 | 253 pure |
| Home Visit Pharmacist Servicereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Home Visit Pharmacist Servicereportable segment | segment assets | at 2022-03-31 | ¥1.6bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥579m |
| Hospital Discharge Support Servicereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2m |
| Hospital Discharge Support Servicereportable segment | employees | at 2022-03-31 | 12 pure |
| Hospital Discharge Support Servicereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥66m |
| Hospital Discharge Support Servicereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥66m |
| Hospital Discharge Support Servicereportable segment | segment assets | at 2022-03-31 | ¥16m |
| Hospital Discharge Support Servicereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥18m |
| Kirari Primereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥8m |
| Kirari Primereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥784,000 |
| Kirari Primereportable segment | employees | at 2022-03-31 | 14 pure |
| Kirari Primereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥433m |
| Kirari Primereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥433m |
| Kirari Primereportable segment | segment assets | at 2022-03-31 | ¥93m |
| Kirari Primereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥259m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥136m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥54m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| —segment total | segment assets | at 2022-03-31 | ¥1.7bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥848m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥140m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥55m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥834m |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥13m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥651m |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥304m |
| Care Planning Servicereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥151,000 |
| Care Planning Servicereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥114,000 |
| Care Planning Servicereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥100m |
| Care Planning Servicereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥100m |
| Care Planning Servicereportable segment | segment assets | at 2021-03-31 | ¥26m |
| Care Planning Servicereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥3m |
| Home Visit Pharmacist Servicereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥64m |
| Home Visit Pharmacist Servicereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥62m |
| Home Visit Pharmacist Servicereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| Home Visit Pharmacist Servicereportable segment | segment assets | at 2021-03-31 | ¥1.3bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥411m |
| Hospital Discharge Support Servicereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥2m |
| Hospital Discharge Support Servicereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥49m |
| Hospital Discharge Support Servicereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥49m |
| Hospital Discharge Support Servicereportable segment | segment assets | at 2021-03-31 | ¥17m |
| Hospital Discharge Support Servicereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥13m |
| Kirari Primereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥343,000 |
| Kirari Primereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥119,000 |
| Kirari Primereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥178m |
| Kirari Primereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥178m |
| Kirari Primereportable segment | segment assets | at 2021-03-31 | ¥45m |
| Kirari Primereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥105m |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥64m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥64m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥5.1bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥5.1bn |
| —segment total | segment assets | at 2021-03-31 | ¥1.4bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥532m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 934
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0404 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 138000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0394 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 127000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0365 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 98000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0282 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 79000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0225 | |
| Number of shares held | CurrentYearInstant | 2738000 | |
| Shareholding ratio | CurrentYearInstant | 0.7825 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 3498600 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 34986 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesLessThanOneUnitMember | 500 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 3499100 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 34986 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | － | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000KurogiTetsujiMember | 1133100 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000ShirooKoheiMember | 98700 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000YamasakiTakeoMember | 39000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000OnishiTomoakiMember | 9000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000OgawaShinjiroMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000MatsuiSetsuoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000TakeiKotaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E37198-000KumamotoNobuharuMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 1279800 | |
| Audit fees reporting company | Prior1YearDuration | 13000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 19000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 1000000 | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Non audit fees reporting company network firms | Prior1YearDuration | 1000000 | JPY |
| Audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Non audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 57000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 57000000 | JPY |
| Share option remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 4 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 5000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 5000000 | JPY |
| Share option remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |